The Scottish Medicines Consortium (SMC) recommend the use of blinatumomab
The Scottish Medicines Consortium (SMC) have today recommended the use of blinatumomab for Philadelphia chromosome negative (Ph-ve), CD19 positive, B cell precursor acute lymphoblastic leukaemia (ALL), who have MRD of at least 0.1%.